Search

An International Ocean Discovery Program (IODP) workshop was held at Sydney University, Australia, from 13 to 16 June 2017 and was attended by 97 scientists from 12 countries. The aim of the workshop was to investigate future drilling opportunities in the eastern Indian Ocean, southwestern Pacific Ocean, and the Indian and Pacific sectors of the Southern Ocean. The overlying regional sedimentary strata are underexplored relative to their Northern Hemisphere counterparts, and thus the role of the Southern Hemisphere in past global environmental change is poorly constrained. A total of 23 proposal ideas were discussed, with ∼  12 of these deemed mature enough for active proposal development or awaiting scheduled site survey cruises. Of the remaining 11 proposals, key regions were identified where fundamental hypotheses are testable by drilling, but either site surveys are required or hypotheses need further development. Refinements are anticipated based upon regional IODP drilling in 2017/2018, analysis of recently collected site survey data, and the development of site survey proposals. We hope and expect that this workshop will lead to a new phase of scientific ocean drilling in the Australasian region in the early 2020s.

The information stored in animal feed databases is highly variable, in terms of both provenance and quality; therefore, data pre-processing is essential to ensure reliable results. Yet, pre-processing at best tends to be unsystematic; at worst, it may even be wholly ignored. This paper sought to develop a systematic approach to the various stages involved in pre-processing to improve feed database outputs. The database used contained analytical and nutritional data on roughly 20 000 alfalfa samples. A range of techniques were examined for integrating data from different sources, for detecting duplicates and, particularly, for detecting outliers. Special attention was paid to the comparison of univariate and multivariate solutions. Major issues relating to the heterogeneous nature of data contained in this database were explored, the observed outliers were characterized and ad hoc routines were designed for error control. Finally, a heuristic diagram was designed to systematize the various aspects involved in the detection and management of outliers and errors.

This study aimed at investigating risk factors for new intramammary infections (IMI) during the dry period in untreated cows from herds using selective dry cow antibiotic therapy (DCT). A total of 980 uninfected quarters in 347 untreated cows from 28 herds using selective DCT were included in a prospective survey. A herd-level questionnaire and an individual cow-level recording sheet were implemented to collect data on putative risk factors. Quarter milk samples were taken at drying-off and on day 3 after calving to assess the occurrence of new IMI during the dry period. A multivariate model including a herd effect as random and a cow effect as repeated was run at the quarter level. Interactions between risk factors and the cow infection status at drying-off (cow infected in at least one quarter v. uninfected) were checked. Three risk factors were found significantly associated with the risk for new IMI without interaction (P < 0.05): cows infected in at least one quarter at drying-off (v. uninfected cows) (relative risks (RR) = 1.58); long preceding lactation (>355 days v. shorter length) (RR = 1.62); long dry period (>65 days v. shorter length) (RR = 1.46). One risk factor acted only in interaction with the cow infection status at drying-off: in cows uninfected at drying-off, the risk for new IMI was significantly higher in cows with short teats (RR = 1.21) when compared with cows with long or normal teats, while the reverse relationship was observed in cows infected at drying-off. Risk factors can be translated in recommendations, for instance to have dry periods not longer than 2 months. Moreover, as suggested by our results, the efficacy of selective DCT towards the prevention of new IMI would be improved if all infected cows were detected and treated. Criteria to accurately identify these infected cows should be therefore further investigated.

Background: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT., Subjects and Measurements: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses., Results: Exenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT., Conclusion: Weekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity., Clinical Trial Registration: clinicaltrials.gov, identifier NCT02794402., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from AstraZeneca. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication., (Copyright © 2023 Stenlid, Cerenius, Wen, Aydin, Manell, Chowdhury, Kristinsson, Ciba, Gjessing, Mörwald, Gomahr, Heu, Weghuber, Forslund and Bergsten.)

Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity., Objective: To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity., Methods: Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m 2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention., Results: Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm 3 ; -989, -114), 2-hour-glucose during OGTT (-15.3 mg/dL; -27.5, -3.1), total cholesterol (11.6 mg/dL; -21.7, -1.5), and BMI (-0.83 kg/m 2 ; -1.68, 0.01) without significant change in liver fat content (-1.36; -3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide-treated patients., Conclusions: Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group., (© 2020 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.)

Chronic and acute tendinopathies are difficult to treat and tendon healing is generally a very slow and incomplete process and our general understanding of tendon biology and regeneration lags behind that of muscle or bone. Although still largely unexplored, several studies suggest a positive effect of nutritional interventions on tendon health and repair. With this study, we aim to reveal effects of a high-glucose diet on tendon neoformation in a non-diabetic rat model of Achilles tenotomy. After surgery animals received either a high-glucose diet or a control diet for 2 and 4 weeks, respectively. Compared to the control group, tendon repair tissue thickness and stiffness were increased in the high-glucose group after 2 weeks and gait pattern was altered after 1 and 2 weeks. Cell proliferation was up to 3-fold higher and the expression of the chondrogenic marker genes Sox9, Col2a1, Acan and Comp was significantly increased 2 and 4 weeks post-surgery. Further, a moderate increase in cartilage-like areas within the repair tissue was evident after 4 weeks of a high-glucose diet regimen. In summary, we propose that a high-glucose diet significantly affects tendon healing after injury in non-diabetic rats, potentially driving chondrogenic degeneration.